38.26
price down icon5.23%   -2.11
after-market Handel nachbörslich: 38.26
loading
Schlusskurs vom Vortag:
$40.37
Offen:
$39.61
24-Stunden-Volumen:
1.77M
Relative Volume:
1.54
Marktkapitalisierung:
$8.27B
Einnahmen:
$1.97B
Nettoeinkommen (Verlust:
$92.93M
KGV:
94.10
EPS:
0.4066
Netto-Cashflow:
$459.60M
1W Leistung:
-3.99%
1M Leistung:
+1.16%
6M Leistung:
-14.63%
1J Leistung:
-9.52%
1-Tages-Spanne:
Value
$38.13
$39.74
1-Wochen-Bereich:
Value
$38.13
$41.44
52-Wochen-Spanne:
Value
$37.74
$49.30

Qiagen Nv Stock (QGEN) Company Profile

Name
Firmenname
Qiagen Nv
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
5,765
Name
Twitter
@QIAGEN
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
QGEN's Discussions on Twitter

Vergleichen Sie QGEN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
QGEN
Qiagen Nv
38.26 8.27B 1.97B 92.93M 459.60M 0.4066
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
437.91 165.21B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
181.77 130.05B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
393.73 31.91B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
103.00 29.38B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
154.73 27.28B 15.41B 1.37B 2.11B 7.50

Qiagen Nv Stock (QGEN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-19 Herabstufung Robert W. Baird Outperform → Neutral
2025-01-06 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-12-10 Hochstufung Jefferies Hold → Buy
2024-10-17 Herabstufung HSBC Securities Buy → Hold
2024-06-27 Hochstufung Wolfe Research Peer Perform → Outperform
2023-12-19 Eingeleitet Wells Fargo Equal Weight
2023-12-13 Eingeleitet Wolfe Research Peer Perform
2023-12-07 Hochstufung Goldman Neutral → Buy
2023-09-12 Eingeleitet Robert W. Baird Outperform
2023-05-23 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-10-18 Eingeleitet Morgan Stanley Equal-Weight
2022-01-18 Hochstufung DZ Bank Hold → Buy
2021-10-15 Fortgesetzt Cowen Market Perform
2021-10-14 Eingeleitet Redburn Buy
2021-07-14 Herabstufung Kepler Buy → Hold
2021-06-03 Eingeleitet Goldman Neutral
2020-10-06 Fortgesetzt BofA Securities Buy
2020-09-28 Hochstufung Kepler Hold → Buy
2020-08-24 Hochstufung Citigroup Neutral → Buy
2020-08-20 Fortgesetzt JP Morgan Overweight
2020-08-17 Hochstufung Berenberg Hold → Buy
2020-08-14 Hochstufung Deutsche Bank Hold → Buy
2020-08-14 Hochstufung Exane BNP Paribas Neutral → Outperform
2020-03-04 Herabstufung Berenberg Buy → Hold
2020-01-08 Eingeleitet Wells Fargo Equal Weight
2020-01-07 Eingeleitet Citigroup Neutral
2019-12-26 Fortgesetzt BofA/Merrill Underperform
2019-11-15 Eingeleitet Stifel Hold
2019-11-14 Hochstufung Evercore ISI In-line → Outperform
2019-11-14 Hochstufung JP Morgan Underweight → Overweight
2019-11-14 Hochstufung Kepler Reduce → Hold
2019-10-17 Hochstufung Wolfe Research Peer Perform → Outperform
2019-10-09 Herabstufung Kepler Hold → Reduce
2019-10-08 Herabstufung Barclays Overweight → Equal Weight
2019-10-08 Herabstufung Deutsche Bank Buy → Hold
2019-10-08 Herabstufung JP Morgan Neutral → Underweight
Alle ansehen

Qiagen Nv Aktie (QGEN) Neueste Nachrichten

pulisher
Apr 04, 2025

Qiagen Announces Voting Rights Update with Bank of America - TipRanks

Apr 04, 2025
pulisher
Apr 04, 2025

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView

Apr 04, 2025
pulisher
Apr 04, 2025

Redburn cuts QIAGEN stock rating, lowers price target to EUR41 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Redburn-Atlantic Downgrades QIAGEN NV (QIA:GR) (QGEN) to Neutral - StreetInsider

Apr 04, 2025
pulisher
Apr 03, 2025

Lab Automation Market Top PlayersF. Hoffmann-La Roche, Qiagen - openPR.com

Apr 03, 2025
pulisher
Apr 02, 2025

Personalized Medicine Market Growth Trends 2025-2033: Transition to Customized Medical Care, Developments in Bioinformatics and Genomics, Growing Prevalence of Chronic Diseases - GlobeNewswire Inc.

Apr 02, 2025
pulisher
Apr 01, 2025

QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts - BioSpace

Apr 01, 2025
pulisher
Apr 01, 2025

Qiagen introduces QIAprep Plasmodium kit to strengthen malaria research efforts - BioSpectrum Asia

Apr 01, 2025
pulisher
Apr 01, 2025

Revolutionary Malaria Test Kit: QIAGEN's New Solution Detects 5 Species with Single-Parasite Sensitivity - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

QIAGEN N.V. Files 2024 Annual Report with SEC - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results - DutchNews.nl

Mar 31, 2025
pulisher
Mar 31, 2025

PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

QIAGEN Releases Full 2024 Annual Report: Access Complete Financial Data and Analysis - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

QIAGEN NV : Jefferies reiterates its Buy rating - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 81% - simplywall.st

Mar 28, 2025
pulisher
Mar 20, 2025

QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label - Business Wire

Mar 20, 2025
pulisher
Mar 18, 2025

Qiagen Manager Pledges Shares in Securities Lending Transaction - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView

Mar 18, 2025
pulisher
Mar 16, 2025

QGEN Stock Might Rise Following Partnership With Genomics England - MSN

Mar 16, 2025
pulisher
Mar 12, 2025

Is it Worth Retaining QIAGEN Stock in Your Portfolio Now? - Yahoo Finance

Mar 12, 2025
pulisher
Mar 11, 2025

Digital Genome Market to Witness Remarkable Growth with QIAGEN, GenomeMe Inc., NanoString Technologies - openPR

Mar 11, 2025
pulisher
Mar 08, 2025

The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses - Yahoo Finance

Mar 08, 2025
pulisher
Mar 07, 2025

Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

FDA clears Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B - Medical Device Network

Mar 07, 2025
pulisher
Mar 06, 2025

Qiagen at TD Cowen Conference: Strategic Growth Plans Unveiled - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday -March 06, 2025 at 09:14 am EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

QIAGEN Gets US FDA Clearance for Second QIAstat-Dx Mini Gastrointestinal Panel -March 06, 2025 at 04:04 am EST - MarketScreener

Mar 06, 2025
pulisher
Mar 06, 2025

How QIAGEN's Latest FDA Win Strengthens Its $4.6B Diagnostic Empire - Stock Titan

Mar 06, 2025
pulisher
Mar 06, 2025

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio - Silicon Canals

Mar 06, 2025
pulisher
Mar 05, 2025

Market is not liking Qiagen's (NYSE:QGEN) earnings decline as stock retreats 4.7% this week - Simply Wall St

Mar 05, 2025
pulisher
Mar 05, 2025

Analyzing Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

QIAGEN Announces Managerial Transactions Involving Performance Stock Units - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

QIAGEN Announces Managerial Stock Transaction - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Qiagen Announces Managerial Stock Unit Grant - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Qiagen Announces Managerial Stock Transactions - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Qiagen Announces Managerial Transaction Involving Restricted Stock Units - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

Qiagen N.V. (QGEN): Among the Cash-Rich Mid Cap Stocks to Buy Now - MSN

Mar 03, 2025
pulisher
Mar 03, 2025

Relative Strength Alert For Qiagen - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey

Mar 03, 2025
pulisher
Mar 03, 2025

BioMérieux: complaint lodged by German company Qiagen -March 03, 2025 at 05:57 am EST - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing - sharewise

Mar 03, 2025
pulisher
Mar 03, 2025

Qiagen Files Patent Infringement Complaint in Germany Against bioMerieux -March 03, 2025 at 05:02 am EST - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

How QIAGEN's Patent Lawsuit Against bioMérieux Could Reshape the TB Testing Market - Stock Titan

Mar 03, 2025
pulisher
Mar 03, 2025

What is Zacks Research’s Estimate for Qiagen Q1 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 03, 2025

QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Qiagen Takes Legal Action To Defend Quantiferon Intellectual Property -March 03, 2025 at 01:04 am EST - Marketscreener.com

Mar 03, 2025
pulisher
Mar 02, 2025

Zacks Research Issues Negative Estimate for Qiagen Earnings - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Zacks Research Forecasts Qiagen's Q4 Earnings (NYSE:QGEN) - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Qiagen (NYSE:QGEN) Reaches New 12-Month LowWhat's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Qiagen (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages - Defense World

Feb 28, 2025

Finanzdaten der Qiagen Nv-Aktie (QGEN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$133.87
price down icon 3.49%
diagnostics_research DGX
$164.18
price down icon 3.78%
diagnostics_research LH
$225.00
price down icon 3.62%
diagnostics_research WAT
$324.92
price down icon 5.85%
diagnostics_research MTD
$1,022.66
price down icon 6.63%
diagnostics_research IQV
$154.73
price down icon 7.73%
Kapitalisierung:     |  Volumen (24h):